Sanofi's $2.56bn bispecific autoimmune deal with Earendil Labs is the second in recent history, and will bolster the French ...

NICE has recommended Tysabri and biosimilar Tyruko as an option for patients with highly active relapsing-remitting multiple ...

Insilico Medicine has entered a multi-year R&D collaboration with Servier, worth up to $888m, to develop and discover new oncology therapies.

Johnson & Johnson (J&J) has completed its acquisition of Halda Therapeutics, a clinical-stage biotechnology company, for ...

Outlook Therapeutics has received the US FDA's CRL regarding the BLA resubmission for ONS-5010/LYTENAVA to treat wet AMD.

In early December, the 2025 updates of China’s NRDL were finalised with a total of 114 drugs, including Western drugs and ...

Maryland’s Prescription Drug Affordability Board (PDAB) serves as a bellwether for how other states may address high drug ...

Data indicating unequal treatment effects in women has prompted calls for more nuance in Alzheimer’s diagnosis and drug ...

Genmab is discontinuing development of acasunlimab after a pipeline review, pivoting focus to other oncology antibodies.

Sanofi has agreed to acquire hepatitis B vaccine manufacturer Dynavax for an equity value of around $2.2bn, bolstering the ...

Emmaus Life Sciences has entered into a licensing and exclusive distribution agreement with NeoImmuneTech (NIT) for Endari, a ...

Zydus Lifesciences Global FZE, a subsidiary of Zydus, has entered into an agreement with Bioeq for the US commercialisation ...